This newsletter presents you the following key sessions:
1. Professor Gerhardt Attard- University College London- Abiraterone acetate plus prednisolone (AAP) with or
without enzalutamide (ENZ) added to androgen deprivation therapy (ADT) compared to ADT alone for men
with high-risk non-metastatic (M0) prostate cancer (PCa): Combined analysis from two comparisons in the
STAMPEDE platform protocol
2. Ramucirumab-erlotinib: a suitable first-line treatment option for EGFR-mutated NSCLC, regardless of TP53
mutation status
3. Trastuzumab deruxtecan as potential novel standard of care for second-line HER2-positive metastatic
breast cancer
4. Pembrolizumab plus chemotherapy for persistent, recurrent, or metastatic cervical cancer
5. Adagrasib demonstrates promising activity in KRASG12C–mutant colorectal cancer